1.Changes in expression of synaptic proteins in brains of patients with Alzheimer's disease.
Ying CAO ; Rivka RAVID ; Zhi-zhong GUAN
Chinese Journal of Pathology 2009;38(12):833-834
Aged
;
Aged, 80 and over
;
Alzheimer Disease
;
metabolism
;
pathology
;
Brain
;
metabolism
;
Dentate Gyrus
;
metabolism
;
Dynamin I
;
metabolism
;
Hippocampus
;
metabolism
;
Humans
;
Monomeric Clathrin Assembly Proteins
;
metabolism
;
Neuropil
;
metabolism
;
Synaptophysin
;
metabolism
2.Clathrin Assembly Lymphoid Myeloid Leukemia-AF10-positive Acute Leukemias: A Report of 2 Cases with a Review of the Literature.
Ji Young HUH ; Soie CHUNG ; Doyeun OH ; Myung Seo KANG ; Hyeon Seok EOM ; Eun Hae CHO ; Mi Hwa HAN ; Sun Young KONG
The Korean Journal of Laboratory Medicine 2010;30(2):117-121
The translocation t(10;11)(p13;q14q21) has been found to be recurrent in acute lymphoblastic and myeloid leukemias, and results in the fusion of the clathrin assembly lymphoid myeloid leukemia (CALM) gene with the AF10 gene; these genes are present on chromosomes 11 and 10, respectively. Because the CALM-AF10 rearrangement is a rare chromosomal abnormality, it is not included in routine molecular tests for acute leukemia. Here, we describe the cases of 2 patients with the CALM-AF10 fusion gene. The first patient (case 1) was diagnosed with T-cell ALL, and the second patient (case 2) was diagnosed with AML. Both patient samples showed expression of the homeobox A gene cluster and the histone methyltransferase hDOT1L, which suggests that they mediate leukemic transformation in CALM-AF10-positive and mixed-lineage leukemia-AF10-positive leukemias. Both patients achieved complete remission after induction chemotherapy. The first patient (case 1) relapsed after double-unit cord blood transplantation; there was no evidence of relapse in the second patient (case 2) after allogenic peripheral blood stem cell transplantation. Since CALM-AF10- positive leukemias have been shown to have poor prognosis with conventional therapy, molecular tests for CALM-AF10 rearrangement would be necessary to detect minimal residual disease during follow-up.
Adolescent
;
Adult
;
Bone Marrow/pathology
;
Chromosomes, Human, Pair 10
;
Chromosomes, Human, Pair 11
;
Cord Blood Stem Cell Transplantation
;
Female
;
Histone-Lysine N-Methyltransferase/genetics/metabolism
;
Homeodomain Proteins/genetics/metabolism
;
Humans
;
Leukemia, Myeloid, Acute/diagnosis/*genetics/therapy
;
Male
;
Monomeric Clathrin Assembly Proteins/*genetics
;
Oncogene Proteins, Fusion/*genetics
;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis/*genetics/therapy
;
Recurrence
;
Transcription Factors/*genetics
;
Translocation, Genetic
3.Molecular mechanisms of androgens regulating the eNOS expression in rat corpus cavernosum.
Guo-Ping XIE ; Ji-Yi XIA ; Jun LIU ; Rui JIANG
National Journal of Andrology 2017;23(1):11-20
Objective:
To investigate whether androgens can regulate the expression of eNOS in rat corpus cavernosum through AKT3, PIK3CA, CALM, and CAV1 and influence erectile function.
METHODS:
Thirty-six 8-week-old male SD rats were randomly divided into groups A (4-week control), B (6-week control), C (4-week castration), D (6-week castration), E (4-week castration + testosterone replacement), and F (6-week castration + testosterone replacement). Both the testis and epididymis were removed from the rats in groups C, D, E and F, and on the second day after surgery, the animals of groups E and F were subcutaneously injected with testosterone propionate at 3 mg per kg of the body weight qd alt while all the others with isodose oil instead. At 4 weeks (for groups A, C and E) and 6 weeks (for groups B, D and F) after treatment, we detected the maximum intracavernous pressure (ICPmax), the mean carotid arterial pressure (MAP) and their ratio (ICPmax/MAP), measured the level of serum testosterone (T), and determined the expressions of eNOS, P-eNOS, AKT3, PIK3CA, CALM and CAV1 in the corpus cavernosum by Western blot and immunohistochemistry.
RESULTS:
No statistically significant differences were observed in the body weight and MAP among different groups. The serum T level and ICPmax/MAP were remarkably lower in groups C and D than in the other four groups (P<0.01) as well as in groups E and F than in A and B (P<0.05) but exhibited no significant differences either between E and F or between A and B. Immunohistochemistry showed that eNOS and P-eNOS were mainly expressed in the vascular endothelial cell membrane and cavernous vascular lumen, while AKT3, PIK3CA, CALM and CAV1 chiefly in the vascular endothelial cell cytoplasm and membrane, with a few in the smooth muscle cells. Western blot analysis manifested that the expressions of eNOS, P-eNOS, AKT3, PIK3CA, CALM and CAV1 were markedly lower in groups C and D than in A, B, E and F (P<0.01) as well as in D than in C (P<0.05) but those in groups E and F did not showed any significant difference from those in A and B, nor E from F or A from B.
CONCLUSIONS
Androgens can improve erectile function by upregulating the expressions of AKT3, PIK3CA, CALM and CAV1 protein molecules and activating eNOS after its phosphorylation, though the exact molecular mechanisms are yet to be further studied.
Animals
;
Blood Pressure
;
Blotting, Western
;
Caveolin 1
;
metabolism
;
Class I Phosphatidylinositol 3-Kinases
;
metabolism
;
Erectile Dysfunction
;
Hormone Replacement Therapy
;
Male
;
Monomeric Clathrin Assembly Proteins
;
metabolism
;
Myocytes, Smooth Muscle
;
Nitric Oxide Synthase Type III
;
metabolism
;
Orchiectomy
;
Penile Erection
;
physiology
;
Penis
;
enzymology
;
metabolism
;
Proto-Oncogene Proteins c-akt
;
metabolism
;
Random Allocation
;
Rats
;
Rats, Sprague-Dawley
;
Testosterone Propionate
;
administration & dosage